Neuphoria Therapeutics Inc (NEUP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $13.42M
Last updated: Nov 17, 2026 at 4:10 PM ET
Neuphoria Therapeutics Inc (NEUP) Statistics
Neuphoria Therapeutics (NEUP) has a market cap of $13.42M. Its share count is up 140.92% from a year earlier. It holds $18.74M more cash than debt, 139.67% of its market cap.
Total Valuation
| Market Cap | $13.42M |
|---|---|
| Latest price (Nov 17, 2026) | $2.27 |
Key Dates
The next earnings report is expected on Nov 18, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 18, 2026 (expected) |
|---|---|
| Last Earnings Date | Sep 2, 2026 |
| Fiscal Year End | June |
Valuation Ratios
| P/B Ratio | 0.5x |
|---|---|
| P/TBV Ratio | 0.8x |
Price Statistics
The stock is down 52.61% over 52 weeks and trades 31.42% below its 50-day average.
| Beta (1Y) | 0.83 |
|---|---|
| 52-Week Change | -52.61% |
| 1-Month Change | -31.42% |
| 3-Month Change | -42.24% |
| 6-Month Change | -52.41% |
| Total Return (1Y) | -52.61% |
| Return vs SPY (1Y) | -63.67% |
| Max Drawdown (1Y) | -58.58% |
| Sharpe Ratio (1Y) | -1.41 |
| Correlation with SPY (1Y) | 0.22 |
| 50-Day Average | $3.31 |
| 200-Day Average | $4.08 |
| 52-Week Range | $2.45 to $5.53 |
| RSI (14 Days) | 10.7 |
| Average Volume (20 Days) | 33.66K |
Financial Position
Current assets cover 18.05x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 18.05x |
|---|---|
| Quick Ratio | 18.05x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| ROE (5Y Average) | -56.12% |
|---|---|
| ROA (5Y Average) | -42.47% |
| ROIC (5Y Average) | -30.40% |
Scores
NEUP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Balance Sheet
Shareholder equity funds 86.57% of the $27.11M in total assets.
| Cash and Equivalents | $18.74M |
|---|---|
| Total Debt | $0 |
| Net Cash | $18.74M |
| Net Cash Per Share | $3.46 |
| Working Capital | $18.52M |
| Shareholder Equity | $23.47M |
| Book Value Per Share | $4.34 |
| Tangible Book Value | $15.97M |
| Tangible Book Per Share | $2.95 |
| Total Assets | $27.11M |
| Total Liabilities | $3.63M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$10.22M |
|---|---|
| FCF Per Share | -$1.89 |
| Depreciation and Amortization | $662.85K |
Trailing 12 months through Sep 30, 2026.
Stock Splits
The last split was a 1-for-12 reverse split on Dec 27, 2024.
| Last Split Date | Dec 27, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NEUP
What is NEUP's market cap?
Neuphoria Therapeutics has a market cap of $13.42M.
How many shares of NEUP are outstanding?
Neuphoria Therapeutics has 5.41M shares outstanding. The count is up 140.92% from a year earlier.
Does NEUP pay a dividend?
No. Neuphoria Therapeutics does not pay a dividend.
How much debt does NEUP have?
Neuphoria Therapeutics has $0 of total debt and $18.74M of cash and equivalents, a net cash position of $18.74M.
NEUP pages: Overview, Earnings, Forecast, Financials, Statistics, Competitors